AZD7648 is a potent and selective DNA-PK inhibitor that enhances radiation, chemotherapy and olaparib activity

par Jacqueline H. L. Fok, Antonio Ramos-Montoya, Mercedes Vazquez-Chantada, Paul W. G. Wijnhoven, Valeria Follia, Neil James, Paul M. Farrington, Ankur Karmokar, Sophie E. Willis, Jonathan Cairns, Jenni Nikkilä, David Beattie, Gillian M. Lamont, M. Raymond V. Finlay, Joanne Wilson, Aaron Smith, Lenka Oplustil O’Connor, Stephanie Ling, Stephen E. Fawell, Mark J. O’Connor, Simon J. Hollingsworth, Emma Dean, Frederick W. Goldberg, Barry R. Davies, Elaine B. Cadogan
Publié 2019

Design and optimisation of dendrimer-conjugated Bcl-2/xL inhibitor, AZD0466, with improved therapeutic index for cancer therapy

par Claire M. Patterson, Srividya B. Balachander, Iain Grant, Petar Pop-Damkov, Brian Kelly, William McCoull, Jeremy Parker, Michael Giannis, Kathryn J. Hill, Francis D. Gibbons, Edward J. Hennessy, Paul Kemmitt, Alexander R. Harmer, Sonya Gales, Stuart Purbrick, Sean Redmond, Matthew Skinner, Lorraine Graham, J. Paul Secrist, Alwin G. Schuller, Shenghua Wen, Ammar Adam, Corinne Reimer, Justin Cidado, Martin Wild, Eric Gangl, Stephen E. Fawell, Jamal Saeh, Barry R. Davies, David J. Owen, Marianne B. Ashford
Publié 2021